HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage

被引:167
|
作者
Jung, KH
Chu, K
Jeong, SW
Han, SY
Lee, ST
Kim, JY
Kim, M
Roh, JK
机构
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Neurol, Clin Res Inst,Stroke & Neural Stem Cell Lab, Seoul 110744, South Korea
[2] Seoul Natl Hosp, Dept Neurol, Seoul, South Korea
[3] Inje Univ, Ilsan Paik Hosp, Dept Neurol, Goyang, South Korea
关键词
HMG-CoA reductase inhibitors; intracerebral hemorrhage; brain edema; apoptosis; inflammation;
D O I
10.1161/01.STR.0000131270.45822.85
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Statins have neuroprotective effects on ischemic stroke. They modify the endothelial function, increase blood flow, and inhibit thrombus formation, which are independent of lipid-lowering effects. However, whether statins have a protective effect toward hemorrhagic stroke is yet unknown. To test this possibility, we attempted to determine the effect of atorvastatin on experimental intracerebral hemorrhage (ICH). Methods-ICH was induced using stereotaxic infusion of collagenase into the left basal ganglia in adult rats. Atorvastatin (1 mg/kg or 10 mg/kg) or phosphate-buffered saline was administered for 2 weeks. To monitor the sensorimotor deficits, limb placing and Rotorod tests were performed. Hematoma volume, brain water content, and hemispheric atrophy were analyzed. Immunohistochemical staining for myeloperoxidase (MPO), microglia (OX42), inducible nitric oxide synthase ( iNOS), or endothelial nitric oxide synthase (eNOS) was performed. Perihematomal cell death was determined by TUNEL staining. Results-The atorvastatin-treated ICH group showed better performance on Rotorod and limb placing tests when compared with the vehicle-treated group (P<0.01). The hematoma volumes between groups were not different, but the brain water content and hemispheric atrophy were reduced in the atorvastatin-treated ICH group. Atorvastatin reduced TUNEL-positive cells, iNOS expression, and MPO-positive or OX42-positive cells in the perihematomal regions in a dose-dependent manner, whereas it increased eNOS expression. Conclusion-The present study shows that atorvastatin reduces the perihematomal cell death via antiinflammation, which is associated with sensorimotor recovery after experimental ICH.
引用
收藏
页码:1744 / 1749
页数:6
相关论文
共 50 条
  • [21] Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction
    Muhlestein, JB
    DRUGS & AGING, 2004, 21 (09) : 583 - 595
  • [22] Atorvastatin (AT), an HMG-CoA reductase inhibitor, reduces plasma cholesterol by alterations in LDL metabolism
    Conde, KA
    Jimenez, M
    Newton, RS
    Fernandez, ML
    FASEB JOURNAL, 1996, 10 (03): : 2947 - 2947
  • [23] An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor
    Black, DM
    Bakker-Arkema, RG
    Nawrocki, JW
    ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (06) : 577 - 584
  • [24] ATORVASTATIN, A HMG-COA REDUCTASE INHIBITOR, AS A NEW THERAPEUTIC STRATEGY IN PLASMODIUM FALCIPARUM MALARIA
    Pradines, Bruno
    Parquet, Veronique
    Briolant, Sebastien
    Almeras, Lionel
    Baret, Eric
    Amalvict, Remy
    Fusai, Thierry
    Rogier, Christophe
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 285 - 286
  • [25] Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage - A case-control study
    Woo, D
    Kissela, BM
    Khoury, JC
    Sauerbeck, LR
    Haverbusch, MA
    Szaflarski, JP
    Gebel, JM
    Pancioli, AM
    Jauch, EC
    Schneider, A
    Kleindorfer, D
    Broderick, JP
    STROKE, 2004, 35 (06) : 1360 - 1363
  • [26] An overview of the clinical safety profile of atorvastatin a new, more effective HMG-CoA reductase inhibitor
    BakkerArkema, RG
    Black, DM
    Nawrocki, JW
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 119 - 119
  • [27] Atorvastatin, a HMG-CoA reductase inhibitor, promotes a Th2 bias and reversal of paralysis in chronic relapsing autoimmune encephalomyelitis
    Youssef, S
    Stuve, O
    Ruiz, PJ
    Steinman, L
    Zamvil, SS
    NEUROLOGY, 2002, 58 (07) : A384 - A384
  • [28] AN HMG-CoA REDUCTASE INHIBITOR, SIMVASTATIN, SUPPRESSES IN VITRO AND IN VIVO PARAMETERS OF INFLAMMATORY SYNOVITIS
    McCarey, D. W.
    Leung, B. P.
    Prach, M. R.
    Crilly, A.
    Madhok, R.
    Liew, F. Y.
    Gracie, J. A.
    Sattar, N.
    McInnes, I. B.
    RHEUMATOLOGY, 2002, 41 : 8 - 8
  • [29] Pleiotropic immunoregulatory properties of the HMG-CoA reductase inhibitor, atorvastatin, on T cells and antigen presenting cells
    Youssef, S
    Prod'homme, T
    Steinman, L
    Zamvil, SS
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 154 (1-2) : 84 - 84
  • [30] Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects
    Cilla, DD
    Whitfield, LR
    Gibson, DM
    Sedman, AJ
    Posvar, EL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) : 687 - 695